Persica Pharma announces positive phase 1b Modic trial of PP353, a novel, non-opioid intradiscal injection to treat chronic low back pain: London, UK Thursday, March 6, 2025, 18:0 ...

Researchers at Washington University and Stanford developed a cannabinoid compound that provides pain relief without ...

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through ...

A study published in the journal Decision Analysis unveils a powerful new tool to tackle the opioid crisis, offering a pathway to slash costs by nearly 30% while saving lives.

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into ...

The global opioid analgesics market is poised for substantial growth, projected to expand from USD 43.3 billion in 2023 to USD 72.0 billion by 2033, at a robust Compound Annual Growth Rate (CAGR) of 5 ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

The opioid-free group also had improved comfort and satisfaction scores. Perspective from Asif M. Ilyas, MD, MBA, FAAOS According to published results, a novel opioid-free pathway may provide ...

A research team has developed a non-opioid medication that shows promise in treating acute and chronic pain. The drug, known ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Evidence has shown that 25% of patients with chronic lower back pain could be suffering from an infection in the disc space.